Table 2.

Approaches for therapy delineated in (pre)clinical IBD studies, since 2016.

Compound	Animal model	Outcome	Ref.
Betulinic acid	Mouse DSS colitis	Decrease of colitis in vivo	(57)
Goat whey	Mouse DNBS colitis	Decrease of colitis in vivo	(58)
Polyphenols	Mouse colitis	Reduced colitis, no MMP-9 activity change	(59)
Eriocitrin	Mouse DSS colitis	Decrease of all severe clinical effects	(60)
Proglitazone	Mouse DSS colitis	Decrease of MMP-9 as colitis biomarker	(61)
Grape seed diet	Piglet DSS colitis	Barrier restauration with decreased MMP-9	(62)
Lupin extract	Mouse TNBS colitis	Less clinical signs and MMP-9 activity	(63)
Anti-oxydant	Chronic TNBS effect	Less clinical parameters and MMP-9 levels	(64)
	Patient cohort
Cannabinoid RA	IBD	Increased mucosal healing	(65)
Il-8 antagonist	UC	Clinical improvement	(66)